Table 2.
Baseline characteristics of patients who underwent 1 year of follow-up and those who did not.
| Patients who were followed up for 1 year (n=18) | Patients who were not followed up for 1 year (n=21) | p value | |
|---|---|---|---|
| Age (years) | 70.3 ± 6.7 | 73.2 ± 11.6 | 0.35 |
| Sex (male/female) | 9/9 | 8/13 | 0.45 |
| Disease duration (years) | 8.6 ± 6.6 | 6.0 ± 3.5 | 0.28 |
| MMSE | 28.3 ± 1.7 | 27.3 ± 2.2 | 0.22 |
| mH&Y | 2.5 ± 0.6 | 2.6 ± 0.8 | 0.90 |
| FFT angle (°) | 12.8 ± 12.9 | 8.0 ± 15.0 | 0.23 |
| SV angle (°) | 6.0 ± 9.8 | 4.5 ± 9.9 | 0.77 |
| UPDRS I | 2.2 ± 1.6 | 2.0 ± 1.2 | 0.92 |
| UPDRS II | 8.6 ± 6.0 | 7.3 ± 5.2 | 0.64 |
| UPDRS III | 14.2 ± 9.4 | 16.2 ± 8.9 | 0.50 |
| UPDRS IV | 2.4 ± 2.8 | 2.4 ± 2.2 | 0.69 |
| UPDRS total | 27.3 ± 13.7 | 28.0 ± 13.9 | 0.88 |
| LED (mg/day) | 636 ± 199.4 | 749.0 ± 349.5 | 0.25 |
MMSE, Mini-Mental State Examination; mH&Y, modified Hoehn & Yahr Scale; FFT, forward flexion of trunk; SV, subjective vertical position; UPDRS, Unified Parkinson's Disease Rating Scale; LED, levodopa-equivalent dose.